Pfizer and Valneva released new data this week from their long‑running Lyme vaccine trial, and the results are… complicated.

Instead of delivering a straightforward answer, the findings raise as many questions as they resolve.

The companies report that their vaccine reached over 70% efficacy—but only after a four‑dose series. And even then, the trial missed its primary statistical goal, they say, largely because fewer Lyme cases occurred during the study than researchers expected.

A second planned analysis did meet the requirement, and Pfizer says it’s still confident enough to move forward with applying for FDA approval.

But here’s where the Lyme community’s collective eyebrow goes up.

No slam dunk

A four‑shot regimen that yields around 70% protection is not exactly a slam‑dunk solution. And realistically, it may be difficult to get large numbers of people to complete a four‑dose series for a vaccine that doesn’t offer near‑complete protection. Even routine two‑dose vaccines struggle with completion rates. Asking for double that is a tall order.

And then there’s the irony that’s hard to ignore: the companies say the trial struggled because “fewer Lyme cases than expected” occurred during the study period. Interesting timing, considering Lyme disease seems to be exploding across the country, with record‑high case estimates and expanding tick ranges.

How does a disease that’s supposedly everywhere suddenly become scarce the moment a vaccine trial needs measurable infections?

And one more thing: even if this vaccine works exactly as advertised, it only targets Lyme disease. It does nothing to prevent babesiosis, Powassan virus, or the many other infections carried by the blacklegged ticks. For many patients, Lyme is only one piece of a much larger puzzle.

Of course, the shadow of Lymerix still hangs over all of this. The last human Lyme vaccine was pulled from the market in 2002 amid lingering controversy. That history left deep scars in the Lyme community—scars that haven’t fully healed. Trust is fragile. Transparency matters.

So where does this leave us?

Maybe the real takeaway is that the Lyme community deserves a prevention strategy that matches the complexity of the threat. A vaccine that covers only one pathogen, requires four doses, and offers only modest protection falls woefully short of what the situation requires.

We need solutions that reflect the full reality of tick‑borne disease — not just the narrow slice that’s easiest to bring to market. Lyme is only one infection in a growing ecosystem of tick-related dangers. A vaccine that targets a single pathogen while ignoring the rest doesn’t match the problem people are actually facing.

Until prevention strategies acknowledge the complexity of tick‑borne illness, the lived experience of patients, and the scale of the problem, it’s hard to see how this vaccine alone will make a meaningful dent in the public health crisis unfolding across the country.

TOUCHED BY LYME is written by Dorothy Kupcha Leland, President of LymeDisease.org. She is co-author of Finding Resilience: A Teen’s Journey Through Lyme Disease and of When Your Child Has Lyme Disease: A Parent’s Survival Guide. Contact her at dleland@lymedisease.org.